Hemostemix (CVE:HEM) Trading Down 22.9% – Time to Sell?

Hemostemix Inc. (CVE:HEM) shares traded down 22.9% during trading on Friday . The stock traded as low as C$0.18 and last traded at C$0.19. 504,239 shares were traded during trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.

Hemostemix Stock Performance

The company has a market cap of C$26.96 million, a price-to-earnings ratio of -5.39 and a beta of 0.20. The firm has a 50-day simple moving average of C$0.19 and a 200 day simple moving average of C$0.11. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.